Intrasense announces the regulatory submission of its Liflow® 1.0 solution (registered trademark of the Myra project), an oncology platform dedicated to the analysis of diagnostic imaging and cancer follow-up.

Liflow®, an oncology diagnostic and longitudinal follow-up platform, provides radiologists with a set of clinical tools addressing all aspects of cancer patient follow-up.

Liflow® represents a paradigm shift in
oncology software solutions, with artificial intelligence algorithms integrated into a single tool, optimizing the power of technology in the service of medicine.

Liflow® provides a unified interface for easy interpretation. By automatically calculating the evolution of lesions, Liflow® optimizes their detection and facilitates medical reporting.

Liflow® is scheduled to go on sale in 2024.

Copyright (c) 2024 CercleFinance.com. All rights reserved.